在早期帕金森病患者中，每日皮下注射利塞那肽可在 12 个月后减少运动障碍的进展。

IF 19.6 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of Internal Medicine Pub Date : 2024-09-01 Epub Date: 2024-09-03 DOI:10.7326/ANNALS-24-01662-JC

Joseph H Friedman

引用次数: 0

摘要

来源引用：Meissner WG, Remy P, Giordana C, et al; LIXIPARK 研究小组。利血那肽治疗早期帕金森病试验。N Engl J Med.2024;390:1176-1185.38598572.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.

Source citation: Meissner WG, Remy P, Giordana C, et al; LIXIPARK Study Group. Trial of lixisenatide in early Parkinson's disease. N Engl J Med. 2024;390:1176-1185. 38598572.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Internal Medicine 医学-医学：内科

CiteScore

23.90

自引率

1.80%

发文量

1136

审稿时长

3-8 weeks

期刊介绍： Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine’s mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.